Skip to main content

Table 5 Adverse events and serious (grade 3 or 4) adverse events reported

From: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

 

MSKCC

Treatment

nal-IRI + 5-FU/LV

Patients

56

toxicities

any grade (%)

grade 3/4 (%)

Nausea

33 (59)

2 (4)

Vomiting

18 (32)

2 (4)

Diarrhea

35 (63)

1 (2)

Fatigue

45 (80)

1 (2)

Anorexia

32 (57)

0 (0)

Neutropenia

16 (29)

1 (2)

Anemia

50 (89)

10 (18)